InsiderTrades.com logo
These AI trades triggered this morning (545% return)
From Prosper Trading Academy   |   Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy
Andrew James King net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew King Biography and Net Worth

Insider of Chinook Therapeutics
Andrew is chief scientific officer at Chinook Therapeutics, overseeing the discovery research, non-clinical development and translational medicine teams. Andrew joined Chinook in May 2019 as head of renal discovery and translational medicine. Prior to joining Chinook, Andrew was senior director of discovery and translational biology at Ardelyx, where he and his teams played key roles in delivering small molecule candidates for the treatment of cardio-renal diseases, as well as elucidating the novel molecular mechanism of action of tenapanor, currently under NDA review by the FDA for the treatment of hyperphosphatemia in dialysis patients. Previously, Andrew spent over seven years at AbbVie in roles of increasing responsibility and led the renal discovery scientific strategy to treat chronic kidney disease. Andrew received his Ph.D. in pharmacology from Michigan State University and completed training in Veterinary Medicine and Surgery at Murdoch University in Australia.

What is Andrew James King's net worth?

The estimated net worth of Andrew James King is at least $773,751.23 as of August 1st, 2023. Mr. King owns 19,157 shares of Chinook Therapeutics stock worth more than $773,751 as of April 26th. This net worth estimate does not reflect any other investments that Mr. King may own. Additionally, Mr. King receives a salary of $651,480.00 as Insider at Chinook Therapeutics. Learn More about Andrew James King's net worth.

How old is Andrew James King?

Mr. King is currently 43 years old. There are 4 older executives and no younger executives at Chinook Therapeutics. The oldest executive at Chinook Therapeutics is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 63 years old. Learn More on Andrew James King's age.

What is Andrew James King's salary?

As the Insider of Chinook Therapeutics, Inc., Mr. King earns $651,480.00 per year. The highest earning executive at Chinook Therapeutics is Mr. Eric L. Dobmeier J.D., Pres, CEO & Director, who commands a salary of $972,190.00 per year. Learn More on Andrew James King's salary.

How do I contact Andrew James King?

The corporate mailing address for Mr. King and other Chinook Therapeutics executives is 740 HEINZ AVENUE, BERKELEY CA, 94710. Chinook Therapeutics can also be reached via phone at (206) 485-7241 and via email at [email protected]. Learn More on Andrew James King's contact information.

Has Andrew James King been buying or selling shares of Chinook Therapeutics?

Andrew James King has not been actively trading shares of Chinook Therapeutics during the last ninety days. Most recently, Andrew James King sold 1,168 shares of the business's stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $39.03, for a transaction totalling $45,587.04. Following the completion of the sale, the insider now directly owns 19,157 shares of the company's stock, valued at $747,697.71. Learn More on Andrew James King's trading history.

Who are Chinook Therapeutics' active insiders?

Chinook Therapeutics' insider roster includes Srinivas Akkaraju (Director), Eric Bjerkholt (CFO), Jerel Davis (Director), Eric Dobmeier (CEO), Tom Frohlich (COO), Alan Glicklich (Insider), and Andrew King (Insider). Learn More on Chinook Therapeutics' active insiders.

Are insiders buying or selling shares of Chinook Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,323 shares worth more than $72,498.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company. Learn More about insider trades at Chinook Therapeutics.

Information on this page was last updated on 8/1/2023.

Andrew James King Insider Trading History at Chinook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Sell1,168$39.03$45,587.0419,157View SEC Filing Icon  
4/3/2023Sell5,000$23.34$116,700.0016,992View SEC Filing Icon  
2/10/2023Sell2,392$23.75$56,810.0019,492View SEC Filing Icon  
1/31/2023Sell3,244$24.68$80,061.9215,081View SEC Filing Icon  
1/3/2023Sell10,000$25.82$258,200.009,992View SEC Filing Icon  
10/6/2022Sell3,557$19.69$70,037.3312,492View SEC Filing Icon  
8/4/2022Sell5,000$20.00$100,000.005,897View SEC Filing Icon  
7/11/2022Sell5,000$18.09$90,450.005,897View SEC Filing Icon  
4/11/2022Sell5,000$15.36$76,800.005,897View SEC Filing Icon  
2/18/2022Sell2,500$13.00$32,500.00View SEC Filing Icon  
2/10/2022Sell2,500$13.31$33,275.00View SEC Filing Icon  
11/9/2021Sell5,000$13.53$67,650.00View SEC Filing Icon  
See Full Table

Andrew James King Buying and Selling Activity at Chinook Therapeutics

This chart shows Andrew James King's buying and selling at Chinook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chinook Therapeutics Company Overview

Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

2 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34
These AI trades triggered this morning (545% return)
From Prosper Trading Academy   |   Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy